行情

CRMD

CRMD

CORMEDIX
AMEX

实时行情|Nasdaq Last Sale

6.15
+0.02
+0.33%
盘后: 6.20 +0.05 +0.81% 17:55 12/06 EST
开盘
6.15
昨收
6.13
最高
6.29
最低
6.07
成交量
17.39万
成交额
--
52周最高
13.70
52周最低
4.860
市值
1.58亿
市盈率(TTM)
-4.1047
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CRMD 新闻

  • Comcast: Undervalued After Recent Pullback
  • Seeking Alpha - Article.1天前
  • Bernie Sanders unveils plan to boost broadband access, break up internet and cable titans
  • CNBC.com.1天前
  • UPDATE 2-Mexico's Televisa wins injunction on part of Disney-Fox deal; merger unaffected
  • Reuters.1天前
  • UPDATE 1-Televisa wins injunction over Disney purchase of Fox assets in Mexico
  • Reuters.1天前

更多

所属板块

制药
+0.45%
制药与医学研究
+0.49%

热门股票

名称
价格
涨跌幅

CRMD 简况

CorMedix Inc. is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications. Neutrolin is an anti-infective solution for the prevention of catheter-related infections and thrombosis in the central venous catheter markets, such as dialysis, critical care and oncology. Neutrolin is a broad-spectrum antimicrobial/antifungal and anticoagulant combination that is active against common microbes, including antibiotic-resistant strains, and may prevent biofilm formation.
展开

Webull提供CorMedix Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。